• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于“细胞疗法、双特异性抗体及其他抗癌免疫疗法”的社论

Editorial on "Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer".

作者信息

Golubovskaya Vita

机构信息

Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA.

出版信息

Cancers (Basel). 2023 Oct 19;15(20):5053. doi: 10.3390/cancers15205053.

DOI:10.3390/cancers15205053
PMID:37894420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10605091/
Abstract

This Special Issue in , "Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer", includes interesting reports and reviews on cell therapies and bispecific antibodies [...].

摘要

本期特刊《细胞疗法、双特异性抗体及其他抗癌免疫疗法》包含了关于细胞疗法和双特异性抗体的有趣报告与综述[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/10605091/9b37fad43693/cancers-15-05053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/10605091/9b37fad43693/cancers-15-05053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/10605091/9b37fad43693/cancers-15-05053-g001.jpg

相似文献

1
Editorial on "Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer".关于“细胞疗法、双特异性抗体及其他抗癌免疫疗法”的社论
Cancers (Basel). 2023 Oct 19;15(20):5053. doi: 10.3390/cancers15205053.
2
TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.T 细胞受体 β 链导向的双特异性抗体用于治疗 T 细胞癌症。
Sci Transl Med. 2021 Mar 10;13(584). doi: 10.1126/scitranslmed.abd3595. Epub 2021 Mar 1.
3
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.
4
Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.双特异性抗体在血液系统恶性肿瘤中的临床开发与治疗应用
Cancer Treat Res. 2022;183:287-315. doi: 10.1007/978-3-030-96376-7_11.
5
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.双特异性免疫调节剂抗体在癌症免疫治疗中的应用
Clin Cancer Res. 2021 Oct 15;27(20):5457-5464. doi: 10.1158/1078-0432.CCR-20-3770. Epub 2021 Jun 9.
6
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer.双特异性抗体靶向髓系细胞作为癌症的新型免疫疗法。
Expert Opin Biol Ther. 2022 Aug;22(8):983-995. doi: 10.1080/14712598.2022.2098675. Epub 2022 Jul 19.
7
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.多发性骨髓瘤中的双特异性单克隆抗体：ASH 2022 年会数据：播客节目。
Adv Ther. 2023 Aug;40(8):3291-3303. doi: 10.1007/s12325-023-02551-9. Epub 2023 Jun 16.
8
Bispecific antibodies in cancer immunotherapy.癌症免疫治疗中的双特异性抗体。
Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17. doi: 10.1177/2515135518763280. Epub 2018 Mar 28.
9
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.双特异性抗体靶向 CD40 和肿瘤相关抗原可促进 T 细胞的交叉呈递，从而产生优于单特异性抗体的抗肿瘤反应。
J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005018.
10
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.靶向癌症的抗体药物偶联物和双特异性抗体：点击化学的应用
Arch Pharm Res. 2023 Mar;46(3):131-148. doi: 10.1007/s12272-023-01433-6. Epub 2023 Mar 6.

引用本文的文献

1
Advances and challenges in anti-cancer vaccines for multiple myeloma.多发性骨髓瘤抗癌疫苗的研究进展与挑战
Front Immunol. 2024 Aug 1;15:1411352. doi: 10.3389/fimmu.2024.1411352. eCollection 2024.

本文引用的文献

1
Recent Advances in Antitumor Dendritic Cell Vaccines.抗肿瘤树突状细胞疫苗的最新进展。
Cancer Biother Radiopharm. 2023 Sep;38(7):450-457. doi: 10.1089/cbr.2023.0041.
2
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.mRNA-LNP 制备的 CAR-NK 细胞在体外和体内杀伤肿瘤靶细胞。
Int J Mol Sci. 2023 Aug 29;24(17):13364. doi: 10.3390/ijms241713364.
3
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations.树突状细胞疫苗：从传统方法到新一代的转变。
Cells. 2023 Aug 25;12(17):2147. doi: 10.3390/cells12172147.
4
CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC).靶向HER1（表皮生长因子受体）的嵌合抗原受体自然杀伤细胞对头颈鳞状细胞癌显示出高效的抗肿瘤活性。
Cancers (Basel). 2023 Jun 13;15(12):3169. doi: 10.3390/cancers15123169.
5
T-Cell Engagers in Solid Cancers-Current Landscape and Future Directions.实体癌中的T细胞衔接器——现状与未来方向
Cancers (Basel). 2023 May 18;15(10):2824. doi: 10.3390/cancers15102824.
6
Dendritic cell vaccine trials in gliomas: Untangling the lines.树突状细胞瘤苗试验在神经胶质瘤中的应用：理清头绪。
Neuro Oncol. 2023 Oct 3;25(10):1752-1762. doi: 10.1093/neuonc/noad088.
7
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.嵌合抗原受体自然杀伤（CAR-NK）细胞疗法的进展：从嵌合抗原受体 T（CAR-T）细胞疗法中吸取的经验教训。
Front Immunol. 2023 May 2;14:1166038. doi: 10.3389/fimmu.2023.1166038. eCollection 2023.
8
Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics.基于树突状细胞的免疫治疗：口腔癌治疗的潜在手段。
Immunotherapy. 2023 Apr;15(6):457-469. doi: 10.2217/imt-2022-0238. Epub 2023 Apr 4.
9
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.NK 细胞治疗血液系统恶性肿瘤的研究进展：NK 细胞来源、持久性和肿瘤靶向性。
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
10
Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs.抗HER2嵌合抗原受体肿瘤浸润淋巴细胞（CAR-TILs）治疗在小鼠和伴侣犬中是安全的且具有抗肿瘤疗效。
Cancers (Basel). 2023 Jan 20;15(3):648. doi: 10.3390/cancers15030648.